![Pyrido[2,3-d]pyrimidin-7(8H)-one,6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl…](https://static.cymitquimica.com/cas-image/386981-pyrido-23-d-pyrimidin-7-8h-one-6-acetyl-8-cyclopentyl-5-methyl-2-5-1-piperazinyl-2-pyridinyl-amino-monohydrochloride.png)
CAS: 827022-32-2 - Pyrido[2,3-d]pyrimidin-7(8H)-one,6-acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]-,monohydrochloride
Formula:C24H29N7O2・ClH
- Synonyms:
- Palbociclib HCl
- Palbociclib hydrochloride
![6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-on…](https://static.cymitquimica.com/products/IN/thumb/DA00392X.jpg)
6-acetyl-8-cyclopentyl-5-methyl-2-[(5-piperazin-1-ylpyridin-2-yl)amino]pyrido[2,3-d]pyrimidin-7-one hydrochloride
CAS:827022-32-2
Formula:
C24H30ClN7O2
Purity:
98%
Color and Shape:
Solid
Molecular weight:
483.9937
Ref: IN-DA00392X
| 1g | 99.00 € | ||
| 5g | 175.00 € | ||
| 10g | 303.00 € | ||
| 25g | 633.00 € | ||
| 5mg | 25.00 € | ||
| 10mg | 28.00 € | ||
| 50mg | 52.00 € | ||
| 100mg | 54.00 € | ||
| 250mg | 50.00 € |
Estimated delivery in United States, on Thursday 2 Jan 2025
Ref: 10-F794120
| 5mg | 45.00 € | ||
| 10mg | 47.00 € | ||
| 50mg | 50.00 € | ||
| 100mg | 53.00 € | ||
| 200mg | 56.00 € | ||
| 500mg | 98.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Palbociclib monohydrochloride
CAS:827022-32-2
Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6, with no inhibition against …
Formula:
C24H29N7O2·HCl
Purity:
100% - 99.79%
Color and Shape:
Solid
Molecular weight:
483.99
Ref: TM-T6239
| 2mg | 35.00 € | ||
| 5mg | 51.00 € | ||
| 10mg | 68.00 € |
Estimated delivery in United States, on Wednesday 8 Jan 2025
PD 0332991 hydrochloride
CAS:827022-32-2
Inhibitor of cyclin D kinases Cdk4 and Cdk6; antineoplastic
Formula:
C24H29N7O2·HCl
Purity:
Min. 95%
Molecular weight:
483.99 g/mol
Ref: 3D-FP137711
| 10mg | To inquire | ||
| 50mg | To inquire |
Estimated delivery in United States, on Wednesday 12 Feb 2025
